FDA Conducting Safety Review of Commonly Used Prostate Cancer Drugs
Links shared publicly online about this topic.
- 1,195total visits
FDA Conducting Safety Review of Commonly Used Prostate Cancer Drugs
fda.gov —
Gonadotropin-Releasing Hormone (GnRH) agonists, a class of medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing analysis of several studies by the U.S. Food and Drug Administration.
View full resource at fda.gov
Tags: Cancer, Cancer Medication, Prostate Cancer, Prostate Cancer Medication, Prostate, Drug, Men's Health, FDA
Most Recently Shared on May 3, 2010 at 3:13 pm By:
FDA Conducting Safety Review of Commonly Used Prostate Cancer Drugs http://bit.ly/dcnL1Q
GnRH Agonist Safety Is Under Review - Renal and Urology News
renalandurologynews.com — “The FDA is conducting a safety review of gonadotropin-releasing hormone (GnRH) agonists, a class of drugs used primarily as a treatment for prostate cancer.” View full resource at renalandurologynews.com
Most Recently Shared on June 15, 2010 at 7:38 am By:
Renal Urology News Medical Publisher, Health News, Nephrology, and Urology
GnRH Agonist Safety Is Under Review: The FDA is conducting a safety review of gonadotropin-releasing hormone (GnRH... http://bit.ly/cu6mf6
Advertisement
